CONFIDENTIAL INVESTMENT MEMORANDUM

Company: Delta Healthcare Services, Inc.
Transaction Type: Leveraged Buyout
Date: October 15, 2025
Fund: Summit Partners VI

EXECUTIVE SUMMARY
Summit Partners proposes to acquire Delta Healthcare Services for $850M enterprise value. Delta is a leading provider of outpatient surgical services with 42 centers across 8 states, serving over 250,000 patients annually.

KEY INVESTMENT HIGHLIGHTS
- Market leader in ambulatory surgical centers (ASC) with 18% regional market share
- Strong unit economics: $4.2M average revenue per center, 28% EBITDA margins
- Recurring revenue model with 75% of procedures covered by Medicare/Medicaid
- Proven acquisition playbook: successfully integrated 12 centers in last 3 years
- Experienced management team with 60+ years combined healthcare experience

FINANCIAL SUMMARY
Enterprise Value: $850M
Equity Investment: $340M (40%)
Senior Debt: $425M (50%)
Mezzanine Debt: $85M (10%)
Revenue (LTM): $176M
EBITDA (LTM): $49M
Entry Multiple: 17.3x EBITDA
Target Exit Multiple: 12.5x EBITDA
Projected IRR: 24-28%
Projected MOIC: 3.2x
Hold Period: 4-5 years

MARKET OVERVIEW
The ASC market is experiencing strong tailwinds driven by:
- Shift from inpatient to outpatient procedures (8% annual growth)
- Cost savings: ASC procedures 45-60% less expensive than hospital-based
- Aging population: 65+ demographic growing at 3.5% CAGR
- Payer preference for lower-cost settings
- Regulatory support under CMS payment models

Total addressable market: $45B (2025)
Projected market growth: 6.5% CAGR through 2030

OPERATIONAL STRATEGY
Year 1-2: Operational Excellence
- Implement centralized procurement (target $3.5M annual savings)
- Roll out standardized clinical protocols across all centers
- Upgrade IT infrastructure for better analytics and scheduling
- Launch physician recruitment program to add 15 surgeons

Year 3-4: Geographic Expansion
- Acquire 8-10 additional centers in high-growth markets (Texas, Florida, Arizona)
- Enter 2 new states through bolt-on acquisitions
- Build de novo centers in underserved markets (target 3 new centers)
- Expand specialty offerings: orthopedics, ophthalmology, pain management

Year 5: Exit Preparation
- Optimize center portfolio (divest underperforming assets)
- Strengthen management team for institutional buyer
- Implement ESG initiatives and reporting framework
- Prepare for strategic sale or IPO

FINANCIAL PROJECTIONS
Year 1: Revenue $195M, EBITDA $54M (27.7% margin)
Year 2: Revenue $228M, EBITDA $65M (28.5% margin)
Year 3: Revenue $275M, EBITDA $80M (29.1% margin)
Year 4: Revenue $340M, EBITDA $102M (30.0% margin)
Year 5: Revenue $425M, EBITDA $132M (31.1% margin)

RISK FACTORS
Regulatory Risk:
- Medicare/Medicaid reimbursement rate cuts (mitigated by diversified payer mix)
- State licensing requirements and certificate of need laws
- Physician ownership restrictions under Stark Law

Operational Risk:
- Integration challenges with acquired centers
- Physician recruitment and retention in competitive markets
- Quality of care incidents impacting reputation
- Cybersecurity and HIPAA compliance

Market Risk:
- Continued shift to value-based care models
- Hospital system competition and vertical integration
- Technology disruption (telemedicine, AI diagnostics)
- Economic downturn reducing elective procedures

MANAGEMENT TEAM
CEO: Dr. Robert Martinez, MD MBA
- 25 years in healthcare operations
- Previously COO of regional hospital network (450 beds)
- Led 15 successful ASC integrations

CFO: Jennifer Wang, CPA
- Former VP Finance at publicly-traded healthcare REIT
- 12 years healthcare finance experience
- Led 3 prior PE-backed companies through exit

COO: Michael Thompson
- 18 years ASC operations experience
- Implemented cost reduction programs saving $12M annually
- Six Sigma Black Belt

Chief Medical Officer: Dr. Sarah Chen, MD
- Board-certified anesthesiologist
- 20 years clinical leadership
- Published researcher in ambulatory care best practices

EXIT STRATEGY
Primary Exit: Strategic Sale
Target buyers: Large healthcare systems, ASC consolidators (United Surgical Partners, Surgery Partners)
Expected valuation: $1.1-1.3B (12.5-14x Year 5 EBITDA)

Alternative Exit: IPO
Market conditions permitting, potential public offering
Comparable public ASC companies trading at 11-15x EBITDA

INVESTMENT TERMS
Equity Commitment: $340M
Management Rollover: $35M (10% of equity)
Management Incentive Plan: 8% option pool
Board Seats: 5 total (3 Summit, 2 Management)
Preferred Return: 8% annual
Catch-up: 20% to GP until 80/20 split
Carried Interest: 20% above 8% hurdle

SOURCES AND USES
Sources:
Senior Debt: $425M
Mezzanine Debt: $85M
Equity: $340M
Total Sources: $850M

Uses:
Purchase Price: $780M
Transaction Fees: $28M
Financing Fees: $18M
Working Capital: $24M
Total Uses: $850M

CONCLUSION
Delta Healthcare Services represents an attractive investment opportunity in the high-growth ambulatory surgical services sector. The combination of strong unit economics, proven acquisition capabilities, and favorable market dynamics positions the investment for superior returns.

We recommend proceeding with definitive due diligence and negotiating binding documentation.